Laboratoire Francais du Fractionnement et des Biotechnologies
🏢 View company profile →97Patents
87Active
97Granted
53Portfolio score
Filing activity: Dec 14, 1998 → Feb 10, 2023 · 23 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7186410B2 | Method for preparing human immunoglobulin concentrates for therapeutic use | Human Necessities | 37 | Expired |
| US7713524B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 26 | Expired |
| US8685725B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 19 | Active |
| US7579170B2 | Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII | Chemistry; Metallurgy | 17 | Expired |
| USRE45992E1 | Optimized FC variants | General | 12 | Active |
| US6932969B1 | Ig fractions having immunomodulatory activity | Emerging Cross-Sectional Technologies | 12 | Expired |
| US8742074B2 | Optimized FC variants | Chemistry; Metallurgy | 12 | Active |
| US10363496B2 | Method for purification of monoclonal antibodies | Physics | 10 | Active |
| US6967239B1 | Method of filtering viruses from a factor VIII solution | Emerging Cross-Sectional Technologies | 8 | Expired |
| US8598319B2 | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins | Chemistry; Metallurgy | 8 | Active |
| US7727743B2 | Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment | Human Necessities | 8 | Active |
| US8501171B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 6 | Active |
| US10034921B2 | Proteins with modified glycosylation and methods of production thereof | Chemistry; Metallurgy | 5 | Active |
| US9694071B2 | Combination of anti-CD20 antibody and PI3 kinase selective inhibitor | Chemistry; Metallurgy | 5 | Active |
| US7771725B2 | Medicinal concentrate of arbovirus specific immunoglobulins and F(ab)'2 and/or Fab fragments | Emerging Cross-Sectional Technologies | 5 | Active |
| US10966977B2 | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders | Chemistry; Metallurgy | 4 | Active |
| US8153382B2 | Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs | Chemistry; Metallurgy | 4 | Active |
| US9873745B2 | Antibody method for treatment of a disease in which the target cells are cells which express CD20 | Chemistry; Metallurgy | 4 | Active |
| US9234045B2 | Monoclonal antibody directed against CD20 antigen | Chemistry; Metallurgy | 4 | Active |
| US9029316B2 | Factor VII composition | Chemistry; Metallurgy | 3 | Active |
| US8409572B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 3 | Active |
| US10174110B2 | Highly galactosylated anti-TNF-α antibodies and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US7541029B2 | Anti-rhesus D monoclonal antibodies | Chemistry; Metallurgy | 3 | Active |
| US6242423A | Freeze-dried placebo pharmaceutical composition designed to imitate a medicine, in particular based on proteins or polypeptides | Human Necessities | 3 | Expired |
| US11091552B2 | Specific binding molecule directed against galectin-3 protein | Chemistry; Metallurgy | 3 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.